B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Category
Proteins, Peptides and Small Molecules
Product Group
Proteins
Purity
>95%
Formulation
Supplied as 0.22µm filtered solution in PBS, 300mM L-Arginine (pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
Molecular Weight
The target protein has a predicted MW of 34.3 kDa.
Synonyms
B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1
